SAB begins phase 1 trial of Covid-19 therapeutic candidate SAB-185
According to the company, SAB-185 is a fully-human, specifically targeted, and broadly neutralising polyclonal antibody therapeutic candidate. Besides potentially treating Covid-19 patients, the drug candidate can provide protective